Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
bladder cancer
Pharma
FDA expands Padcev-Keytruda combo to more MIBC patients
Padcev and Keytruda have become the first muscle-invasive bladder cancer treatment that covers patients regardless of cisplatin eligibility.
Angus Liu
Jul 10, 2026 1:10pm
AZ gains on Merck with 2nd bladder cancer nod for Imfinzi
May 28, 2026 4:39pm
J&J bladder cancer survey shows toll of surgery, BCG treatment
May 14, 2026 4:00pm
AZ’s Imfinzi gains ground on Keytruda in bladder cancer race
May 14, 2026 11:52am
SCOTUS order advances racketeering case involving Takeda, Lilly
Mar 24, 2026 8:45am
Padcev-Keytruda combo wins in MIBC amid evolving landscape
Feb 27, 2026 10:00am
